This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Formation | 1953 |
---|---|
Founder | James Ernest Ayre M.D. |
Type | not-for-profit organization |
Services | Programs include: Aggressive Cancer Research, The Breast Cancer Project, The Children's Cancer Project, Fighting Childhood Leukemia, NCC Special Programs, and the Prostate Cancer Project |
Website | https://nationalcancercenter.org/ |
National Cancer Center ("NCC" or "Center"), founded in 1953, is a (501)(c)(3) not-for-profit organization in the United States that funds young cancer researchers who are working to discover how the body's immune system sees and responds to cancer when it initially develops and why certain cancer cells are resistant to different treatments. The organization also provides educational information to the public on the prevention, diagnosis and treatment of cancer. [1]
Grants are awarded based on the recommendations of NCC's Scientific Advisory Board, which uses National Institutes of Health evaluation standards. Scientific Advisory Board members are cancer research professionals, headed by Dr. Darell Bigner, founder and director of Duke University’s Preston Robert Tisch Brain Tumor Center, [2] the largest brain tumor research facility in the country. Other Grant Review Committee members represent such institutions as the Dana-Farber Cancer Institute, the University of Pittsburgh Cancer Institute and Duke University Medical Center.
The Center's funding of basic research epitomizes the high standards of founder Dr. James Ernest Ayre. Dr. James Ernest Ayre was a ground-breaking gynecologist dedicated to cancer research by ways of immunology and cytology detection. [3] He was the co-inventor of the Ayre spatula, a wooden device used to collect cervical cells in women to detect cancer, and a strong advocate for early cancer screening. [4]
The National Cancer Center funds these research programs: The Breast Cancer Project, The Children’s Cancer Project, Aggressive Cancer Research, Fighting Childhood Leukemia, and The Prostate Cancer Project.[ citation needed ]
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.
Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".
Ludwig Cancer Research is an international community of scientists focused on cancer research, with the goal of preventing and controlling cancer. It encompasses the Ludwig Institute for Cancer Research, an international non-profit organization founded in 1971 by philanthropist Daniel K. Ludwig. The Institute is headquartered in New York City, with a European office located in Zürich. There are currently three Ludwig Branches: Ludwig Lausanne, Ludwig Oxford and Ludwig Princeton. In addition, there are six Ludwig Centers at leading institutions across the United States of America. Together, the Institute, Branches and Centers are known as Ludwig Cancer Research.
The Jackson Laboratory is an independent, non-profit biomedical research institution which was founded by Clarence Cook Little in 1929. It employs over 3,000 employees in Bar Harbor, Maine; Sacramento, California; Farmington, Connecticut; Shanghai, China; and Yokohama, Japan. The institution is a National Cancer Institute-designated Cancer Center and has NIH Centers of Excellence in aging and systems genetics. The stated mission of The Jackson Laboratory is "to discover the genetic basis for preventing, treating and curing human diseases, and to enable research and education for the global biomedical community."
The Children's Oncology Group (COG), a clinical trials group supported by the National Cancer Institute (NCI), is the world's largest organization devoted exclusively to pediatric cancer research. The COG conducts a spectrum of clinical research and translational research trials for infants, children, adolescents, and young adults with cancer.
The Duke University School of Medicine, commonly known as Duke Med, is the medical school of Duke University. It was established in 1925 by James B. Duke.
Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.
The McArdle Laboratory for Cancer Research is a basic cancer research facility located on the University of Wisconsin–Madison campus in Madison, Wisconsin. It houses the university's Department of Oncology. The staff of the McArdle Laboratory numbers approximately 200. Twenty-eight faculty members lead research groups focused on various fields such as cancer virology, signal transduction, cell cycle, cancer genetics, and carcinogenesis.
John E. Niederhuber was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.
The University of Wisconsin Carbone Cancer Center (UWCCC) is a comprehensive cancer center in Wisconsin, as designated by the National Cancer Institute (NCI), the lead federal agency for cancer research. It is an integral part of both the University of Wisconsin (UW) and the University of Wisconsin Hospital and Clinics. It is located in Madison, Wisconsin.
The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is a cancer treatment, research and education institution with six locations in the St. Louis area. Siteman is the only cancer center in Missouri and within 240 miles of St. Louis to be designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). Siteman is also the only area member of the National Comprehensive Cancer Network, a nonprofit alliance of 32 cancer centers dedicated to improving the quality and effectiveness of cancer care.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center in Houston, Texas. Allison is Regental Professor and Founding-Director of James P. Allison Institute at the MD Anderson Cancer Center.
Dr. Matthias Gromeier is a Professor in the Department of Neurosurgery at Duke University Medical Center, who has developed a way to re-engineer a poliovirus to inspire the human immune system to kill cancer cells in a specific set of cancers. The re-engineered virus, called PVSRIPO, cannot replicate itself in normal cells, but can replicate itself in cancer cells that have an overabundance of the protein marker that the poliovirus targets.
PVSRIPO, or PVS-RIPO, is the name of a modified polio virus that has recently shown promise for treating cancer. It is the focus of clinical trials being conducted at Duke University.
Dafna Bar-Sagi is a cell biologist and cancer researcher at New York University School of Medicine. She is the Saul J. Farber Professor in the department of biochemistry and molecular pharmacology and the department of medicine and senior vice president and vice dean for science at NYU Langone Health. Bar-Sagi has been a member of scientific advisory boards, including the National Cancer Institute, Starr Cancer Consortium, and Pancreatic Cancer Action Network.
Peter Edward Fecci is an American neurosurgeon, professor and researcher. He is an Associate Professor of Neurosurgery, Pathology and Immunology at Duke University School of Medicine. He also serves as Director of the Duke Center for Brain and Spine Metastasis, Director of the Brain Tumor Immunotherapy Program, Residency Program Director, and Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke.
Michelle Leigh Monje-Deisseroth is a neuroscientist and neuro-oncologist. She is a professor of neurology at Stanford University and an investigator with the Howard Hughes Medical Institute. She develops new treatments for diffuse intrinsic pontine glioma.
Duane A. Mitchell is an American physician-scientist and university professor. He is currently employed at the University of Florida College of Medicine, in Gainesville, Florida as the Assistant Vice President for Research, Associate Dean for Translational Science and Clinical Research, and Director of the University of Florida (UF) Clinical and Translational Science Institute. He is the Phyllis Kottler Friedman Professor in the Lillian S. Wells Department of Neurosurgery. and co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy. Mitchell is also the founder, President, and Chairman of iOncologi, Inc., a biotechnology company in Gainesville, FL specializing in immuno-oncology.
Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.
Amy B. Heimberger is an American neurosurgeon and physician-scientist. She is the Jean Malnati Miller Professor of Neurological Surgery, vice-chair for research in the department of Neurological Surgery at Feinberg School of Medicine and scientific director of The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center.